What is GlobeImmune?
GlobeImmune, Inc. is a biopharmaceutical firm dedicated to creating innovative therapeutic products targeting cancer and infectious diseases. The company leverages its proprietary Tarmogen platform, with key candidates like GS-4774 in Phase 2 trials for hepatitis B virus and other oncology-focused treatments such as GI-6301 and GI-6207. GlobeImmune's pipeline also includes preclinical development for tuberculosis, HIV, and hepatitis D virus, alongside strategic collaborations with industry leaders Gilead Sciences and Celgene Corporation. Formerly Ceres Pharmaceuticals, Inc., the company rebranded in May 2001 and has been headquartered in Louisville since its founding in 1995.
How much funding has GlobeImmune raised?
GlobeImmune has raised a total of $15M across 1 funding round:
Stock Offering
$15M
Stock Issuance/Offering (2014): $15M, investors not publicly disclosed
What's next for GlobeImmune?
The recent major strategic investment signals a pivotal phase for GlobeImmune, likely enabling the acceleration of its clinical trials and the expansion of its therapeutic pipeline. This capital infusion is expected to support the advancement of its oncology and infectious disease programs, potentially moving them closer to commercialization. The company's focus on its Tarmogen platform and its established collaborations suggest a strategic direction aimed at leveraging its unique technology for significant therapeutic breakthroughs.
See full GlobeImmune company page
